Key result
Second-generation antipsychotics were associated with significantly higher pulse wave velocity (4.91 vs 4.73, p=0.048) in patients with schizophrenia and bipolar disorder compared to healthy controls.
Why the study?
Does the use of second-generation antipsychotics increase pulse wave velocity in patients with schizophrenia and bipolar disorder compared to healthy controls?
Cross-Sectional (n=96)
No
Does the use of second-generation antipsychotics increase pulse wave velocity in patients with schizophrenia and bipolar disorder compared to healthy controls?
Patients with schizophrenia and bipolar disorder taking second-generation antipsychotics exhibit increased arterial stiffness compared to healthy controls, suggesting a potential mechanism for their elevated cardiovascular risk.
May link antipsychotics to CV risk via stiffness in these patients; leaves open causality and requires prospective studies.
OBJECTIVE: That treatment with second-generation antipsychotics (SGAs) causes metabolic side effects and atherosclerosis in patients with schizophrenia and bipolar disorder (BD) is well-known. Increased arterial stiffness is an important marker of arteriosclerosis and has been identified as an independent risk factor for cardiovascular diseases. We measured pulse wave velocity (PWV) as a marker of arteriosclerosis in patients with schizophrenia and BD who use SGAs. METHODS: Patients and controls were collected from our psychiatry outpatient clinics or family medicine. Mental illness was diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition. Mean age, gender, systolic and diastolic blood pressure, body mass index, Framingham risk score (FRS), etc. were determined. Simultaneous electrocardiography and pulse wave were recorded with an electromyography device. The photo-plethysmographic method was used to record the pulse wave. Inclusion criteria included use of SGAs for at least the last six months. Patients with diseases that are known to cause stiffness and the use of typical antipsychotics were excluded. CONCLUSION: This study supported the liability to stiffness in patients with schizophrenia and BD. Using SGAs may contribute to arterial stiffness in these patients.
No takes yet. Share an insight, caveat, or question.
Fındıklı et al. (2016) conducted a cross-sectional in Schizophrenia and Bipolar Disorder (n=96). Second-generation antipsychotics vs. Healthy controls was evaluated on Pulse wave velocity (PWV) (p=0.048). Second-generation antipsychotics were associated with significantly higher pulse wave velocity (4.91 vs 4.73, p=0.048) in patients with schizophrenia and bipolar disorder compared to healthy controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: